Start Free
Longevity

NMN & Nicotinamide Riboside

Also known as: nicotinamide mononucleotide, NR, nicotinamide riboside, NAD+ booster

They reliably raise NAD+ in humans. Whether raising NAD+ does anything you would notice is the question nobody has answered.

Grade CMixed or limited evidence
Studied dose250-1,000 mg/day (NR trials clustered at 300-1,000 mg; NMN at 250-500 mg)
TimingMorning is conventional, on the theory …
EvidenceGrade C
CategoryLongevity

Human trials consistently confirm the biochemical effect — blood NAD+ rises, and the compounds are well tolerated. Functional outcomes are a different story: results are small, inconsistent, and confined to secondary endpoints in short trials.

NAD+ boosters are the flagship of the consumer longevity market, and they are a good test of whether you can tell a validated mechanism from a validated outcome.

The mechanism half is genuinely solid. NAD+ is essential to cellular metabolism and to the sirtuin enzymes that David Sinclair's lab made famous. It declines substantially with age across tissues. Give mice NMN and a startling range of things improve — insulin sensitivity, mitochondrial function, endurance, even some measures of vascular ageing. That is a real and reproducible animal literature.

The human half is where it thins out. The good news, and it is real, is that the compounds work biochemically: multiple well-conducted trials confirm that oral NR and NMN raise blood NAD+ substantially and are well tolerated over months. That is not nothing — plenty of supplements fail this basic test.

What has not followed is function. The Martens trial in middle-aged and older adults found NR raised NAD+ reliably and produced only a hint of blood-pressure and arterial-stiffness benefit in a subgroup. A Science paper in prediabetic women found NMN improved muscle insulin sensitivity — a real result on a real endpoint, in 25 people over ten weeks. Other trials report modest changes in walking speed or fatigue, and several report nothing. The pattern is a small literature of small trials, short durations, secondary endpoints, and inconsistent direction.

That is exactly what an early-stage research programme looks like, and it is being sold as a finished product at a hundred dollars a month. The regulatory picture adds to the mess: the FDA has taken the position that NMN is excluded from the supplement category because it was investigated as a drug, leaving its US availability unsettled.

There is also a mechanistic worry worth stating. NAD+ fuels PARP-mediated DNA repair and sirtuin activity, but some cancer cells are avid NAD+ consumers, and rodent work has raised the possibility of accelerated tumour progression. No human signal exists, and no trial has been long enough to find one.

Grade C is generous, and it reflects the mechanism and the tolerability. If you buy these, buy them knowing you are funding a hypothesis.

How it works

NAD+ is a coenzyme required for hundreds of redox reactions and is the obligatory substrate for sirtuins and PARPs, the enzyme families implicated in DNA repair and metabolic regulation. NAD+ declines with age. NMN and NR are precursors that raise it; the unproven link is whether restoring the molecule restores the function.

What the evidence supports

  • Raises blood NAD+ levels the one thing consistently demonstrated in humansA
  • Improves muscle insulin sensitivity one small trial in prediabetic women; unreplicatedC
  • Improves cardiovascular or physical function markers small, inconsistent, mostly subgroup findingsC
  • Slows human ageing or extends healthspan no trial has tested this; the entire premise remains a hypothesisD

Safety

Well tolerated in trials up to a year at doses around 1,000 mg/day, with no consistent adverse-event signal. The honest caveat is duration: nobody has taken these for a decade under observation. The theoretical cancer concern — NAD+ supports proliferation in some tumour cell lines — has no human evidence behind it and no trial long enough to rule it out.

Reported side effects

  • Generally mild: nausea, fatigue, headache
  • Flushing reported occasionally

Interactions

  • No established drug interactions.
  • Caution is advised in active malignancy on theoretical grounds — discuss with an oncologist.

This guide is educational, not medical advice. Talk to a physician or pharmacist before starting any supplement, especially alongside prescription medication or a medical condition.

Common questions

What does NMN & Nicotinamide Riboside do?
They reliably raise NAD+ in humans. Whether raising NAD+ does anything you would notice is the question nobody has answered. Its best-supported effects are raises blood NAD+ levels.
Does NMN & Nicotinamide Riboside actually work?
Mixed or limited evidence (grade C). Human trials consistently confirm the biochemical effect — blood NAD+ rises, and the compounds are well tolerated. Functional outcomes are a different story: results are small, inconsistent, and confined to secondary endpoints in short trials.
How much NMN & Nicotinamide Riboside should I take?
The studied range is 250-1,000 mg/day (NR trials clustered at 300-1,000 mg; NMN at 250-500 mg), once daily, usually in the morning. Start at the low end — more is not better once the effective range is covered.
When should I take NMN & Nicotinamide Riboside?
Morning is conventional, on the theory that NAD+ follows a circadian rhythm — this is reasoning from mouse biology rather than human data.
Is NMN & Nicotinamide Riboside safe?
Well tolerated in trials up to a year at doses around 1,000 mg/day, with no consistent adverse-event signal. The honest caveat is duration: nobody has taken these for a decade under observation. The theoretical cancer concern — NAD+ supports proliferation in some tumour cell lines — has no human evidence behind it and no trial long enough to rule it out. The most reported side effects are generally mild: nausea, fatigue, headache, flushing reported occasionally.
What should you not mix NMN & Nicotinamide Riboside with?
No established drug interactions. Caution is advised in active malignancy on theoretical grounds — discuss with an oncologist. Ask a pharmacist or physician before combining it with prescription medication.

References

Evidence review last updated

  1. Martens, C. R., et al. (2018). "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications. Source
  2. Yoshino, M., et al. (2021). "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. Source

Related

Phenotypic Age → Metabolic Age → VO2 Max Estimator → Biological Age vs Chronological Age: What Really Matters → Cold Plunge and Healthspan: What the Evidence Actually Supports → Biomarkers: The Numbers That Actually Predict Your Health →